Recent developments in psoriasis

Recent developments reported on Healio.com/Dermatology have included survey results finding that Humira is the most prescribed biologic for treating psoriasis when compared with Enbrel.

Other developments included study results showing psoriasis having an increased risk of new-onset migraine dependent on disease severity:

Survey finds Humira most prescribed biologic for treating psoriasis compared with Enbrel

A survey by Decision Resources Group found that Humira was the biologic most prescribed for moderate-to-severe psoriasis when compared with Enbrel, according to a press release.

However, Enbrel (etanercept, Amgen/Pfizer) had a more favorable reimbursement environment compared with Humira (adalimumab, AbbVie), according to the release. Read more

Psoriasis, psoriatic arthritis associated with increased migraine risk

Patients with psoriasis had an increased risk of new-onset migraine dependent on disease severity, and patients with psoriatic arthritis also had an increased risk, according to recently published study results.

Researchers studied a nationwide Danish cohort of 5,379,859 citizens aged 18 years and older from 1997 to 2011. The cohort included 53,006 patients with mild psoriasis, 6,831 patients with severe psoriasis and 6,243 patients with psoriatic arthritis. Read more

Some patients with psoriatic arthritis may benefit from Cosentyx

About half of patients with psoriatic arthritis who received subcutaneous infusions of 150 mg or 300 mg of Cosentyx achieved a 20% response to treatment, according to a recently published study.

Researchers conducted a phase 3, double-blind, placebo-controlled study of 397 patients with psoriatic arthritis at 76 centers in Asia, Australia, Canada, Europe and the U.S. between April and November 2013. Read more

Can-Fite announces registered direct offering

Can-Fite BioPharma Ltd. announced that it has entered into agreements with institutional investors to receive gross proceeds of $9 million.

The biotechnology company recently announced it is preparing the protocol for another advanced psoriasis trial based on positive data from further analysis of its completed phase 2/3 study that suggested CF101 was a potential systematic therapy for patients with moderate-to-severe psoriasis. Read more